Arcus Biosciences (RCUS) FY2024 results: revenue $258 million, up 120.5% on the year
Arcus Biosciences, Inc. (RCUS) reported revenue of $258 million for fiscal 2024, the year ended 31 December 2024, up 120.5% on the year before. Net income was -$283 million, and diluted earnings per share $-3.14. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2025.
Revenue
$258 million
+120.5% on the year
FY2017FY2024
Operating margin
-127.9%
-290.6% a year earlier
FY2017FY2024
Net income
-$283 million
FY2017FY2024
Diluted EPS
-$3.14
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
-170
-306
438
Capital expenditure
6.0
24.0
6.0
-75.0%
Free cash flow
-176
-330
432
Free cash flow margin
-68.2%
-282.1%
385.7%
Cash from investing
-84.0
194
-413
Cash from financing
277
33.0
33.0
+739.4%
Depreciation and amortisation
10.0
8.0
6.0
+25.0%
Share-based compensation
76.0
73.0
65.0
+4.1%
Diluted shares, weighted
90m
74m
72m
+21.8%
Shares outstanding at period end
92m
76m
73m
+22.1%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
485
462
657
+5.0%
Debt
48.0
0.0
0.0
Operating lease liabilities
99.0
110
117
-10.0%
Other liabilities
518
523
571
-1.0%
Total liabilities and equity
1,150
1,095
1,345
+5.0%
Fixed assets
47.0
51.0
35.0
-7.8%
Investments
842
739
932
+13.9%
Cash and equivalents
150
127
206
+18.1%
Other assets
111
178
172
-37.6%
Total assets
1,150
1,095
1,345
+5.0%
10-K for the year ended 31 December 2024, filed 25 February 2025: the filing.